Counterfeits quantified

$75 billion. That's an estimate of the revenue generated in the 2010 counterfeit drug market, according to The Center for Medicine in the Public Interest. The center's president, former FDA associate commissioner Peter Pitts, bases the figure on government information. He projects growth of 20% annually in the coming years. News

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.